Maplight Therapeutics (NASDAQ:MPLT) Insider Erin Pennock Foff Sells 10,576 Shares

Maplight Therapeutics, Inc. (NASDAQ:MPLT) insider Erin Pennock Foff sold 10,576 shares of the business’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $28.20, for a total value of $298,243.20. Following the transaction, the insider owned 374,549 shares of the company’s stock, valued at approximately $10,562,281.80. The trade was a 2.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Erin Pennock Foff also recently made the following trade(s):

• On Wednesday, May 6th, Erin Pennock Foff sold 24,052 shares of Maplight Therapeutics stock. The shares were sold at an average price of $28.76, for a total value of $691,735.52.
• On Monday, May 4th, Erin Pennock Foff sold 15,652 shares of Maplight Therapeutics stock. The shares were sold at an average price of $27.96, for a total value of $437,629.92.

Maplight Therapeutics Price Performance

MPLT traded up $1.12 during trading hours on Wednesday, reaching $29.04. 267,979 shares of the company’s stock traded hands, compared to its average volume of 342,018. The company’s 50-day moving average price is $22.60. Maplight Therapeutics, Inc. has a 52-week low of $12.24 and a 52-week high of $33.28. The firm has a market capitalization of $1.24 billion and a price-to-earnings ratio of -0.73.

Maplight Therapeutics (NASDAQ:MPLT) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($2.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.05) by ($1.42). Sell-side analysts forecast that Maplight Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Analysts Set New Price Targets

MPLT has been the subject of a number of research analyst reports. TD Cowen initiated coverage on Maplight Therapeutics in a research report on Tuesday, April 7th. They set a “buy” rating for the company. HC Wainwright initiated coverage on Maplight Therapeutics in a research report on Monday. They set a “buy” rating and a $45.00 target price for the company. Needham & Company LLC initiated coverage on Maplight Therapeutics in a research report on Wednesday, April 8th. They set a “buy” rating and a $37.00 target price for the company. Weiss Ratings initiated coverage on Maplight Therapeutics in a research report on Thursday, January 22nd. They set a “sell (e)” rating for the company. Finally, Wall Street Zen lowered Maplight Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.43.

Maplight Therapeutics News Roundup

Here are the key news stories impacting Maplight Therapeutics this week:

• Positive Sentiment: Needham reaffirmed its “Buy” rating on MPLT, signaling continued analyst conviction that the shares have upside. Needham Reaffirms Buy
• Positive Sentiment: HC Wainwright initiated/updated coverage with a “Buy” rating and a $45 price target (roughly mid‑50% upside from recent levels), which can attract buyers and support the rally. Many outlets reported the new coverage and target. HC Wainwright Coverage & Target
• Neutral Sentiment: Morningstar and market quote pages show current trading context (price, volume, 50‑day moving average) that traders use to gauge technical support/resistance. Use these pages for up‑to‑date quotes. Morningstar Quote
• Negative Sentiment: HC Wainwright’s detailed forecasts also project larger net losses over 2026–2027 (FY2026 EPS ~ -$4.34; FY2027 EPS ~ -$5.25) and quarterly losses through 2027 — data that underscores continued cash‑burn and execution risk for a clinical‑stage biotech. This raises downside risk if clinical or financing progress stalls. Analyst Estimates
• Negative Sentiment: Recent reported results included a sizable Q1 EPS miss (reported -$2.47 vs. consensus -$1.05), which remains a reminder of earnings volatility and could pressure sentiment if follow‑up data or guidance are weak. Recent Earnings Miss

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Fcpm Iii Services B.V. bought a new position in shares of Maplight Therapeutics in the 4th quarter worth $56,672,000. T. Rowe Price Investment Management Inc. bought a new position in shares of Maplight Therapeutics in the 4th quarter worth $49,154,000. Goldman Sachs Group Inc. bought a new position in shares of Maplight Therapeutics in the 4th quarter worth $34,026,000. Nan Fung Group Holdings Ltd bought a new position in shares of Maplight Therapeutics in the 4th quarter worth $17,060,000. Finally, 5AM Venture Management LLC bought a new position in shares of Maplight Therapeutics in the 4th quarter worth $16,687,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.